<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423826</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000518230</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-2006-059</secondary_id>
    <secondary_id>WSU-112506MP2F</secondary_id>
    <nct_id>NCT00423826</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease</brief_title>
  <official_title>A Pilot Study of Double Cord Blood Stem Cell Transplantation in Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor
      umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
      It also stops the patient's immune system from rejecting the donor's stem cells. The donated
      stem cells may replace the patient's immune cells and help destroy any remaining cancer or
      abnormal cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can
      also make an immune response against the body's normal cells. Giving tacrolimus and
      mycophenolate mofetil before the transplant may stop this from happening.

      PURPOSE: This clinical trial is studying how well umbilical cord blood stem cell transplant
      works in treating patients with hematologic cancer or other disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the efficacy of double umbilical cord blood stem cell transplantation using a
           conditioning regimen comprising lower doses of busulfan and fludarabine phosphate and
           low-dose total body irradiation, in terms of stem cell engraftment at 60 days post
           transplantation, in patients with hematologic cancer or other diseases.

        -  Determine the merits of conducting a larger, comparative study of this regimen.

      Secondary

        -  Determine mortality within 100 days of transplantation in these patients.

      OUTLINE: This is a pilot study.

        -  Reduced-intensity conditioning regimen: Patients receive busulfan IV over 3 hours on
           days -9 to -8 and fludarabine phosphate IV on days -7 to -3. Patients then undergo
           low-dose total body irradiation on day 0.

        -  Graft-versus-host disease prophylaxis: Patients receive tacrolimus IV twice daily and
           mycophenolate orally or IV three times daily beginning on day -3.

        -  CNS prophylaxis and/or treatment: Patients with a history of CNS involvement receive
           prophylactic cytarabine (Ara-C) intrathecally (IT) prior to transplant. Patients also
           undergo lumbar puncture (LP) to test for active CNS disease. Patients with cerebrospinal
           fluid positive for leukemia receive Ara-C IT every 2-3 days until a repeat LP shows no
           remaining leukemic cells. Three days after the last LP and after one final dose of
           Ara-C, patients begin the conditioning regimen.

        -  Double umbilical cord blood (UCB) donor stem cell transplantation (SCT): Patients
           undergo double UCB donor SCT on day 0.

      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Precancerous Condition</condition>
  <condition>Secondary Myelofibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>3 mg/kg intravenously over 3 hours</description>
    <other_name>Busulfex®</other_name>
    <other_name>Myleran®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Patients with previous history of CNS involvement will receive pre-transplant intrathecal Cytarabine (Ara-C) (30 mg/M2) therapy.</description>
    <other_name>DepoCyt(TM)</other_name>
    <other_name>Liposomal Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine phosphate</intervention_name>
    <description>25 mg/M2/day IV</description>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Orally at the dose of 1 gm every 8 hours.</description>
    <other_name>Cellcept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>0.015 mg/kg IV every 12 hours by continuous infusion.</description>
    <other_name>Advagraf</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>10 days post drug intervention</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>10 days post drug intervention</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>10 days post drug intervention</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of 1 of the following:

               -  Acute myeloid leukemia meeting the following criteria:

                    -  M0-M7 histologic subtypes by French-American-British classification

                    -  Previously treated disease

                    -  Meets 1 of the following criteria:

                         -  Persistent disease as evidenced by 5-30% persistent blasts in bone
                            marrow after induction or salvage therapy

                         -  In second or subsequent complete remission (CR)

                         -  In first CR with 1 of the following high-risk features:

                              -  Philadelphia chromosome present

                              -  Noncore-binding factor type of chromosomal abnormalities

               -  Myelodysplastic syndromes with 1 of the following International Prognostic
                  Scoring System (IPSS) scores:

                    -  Intermediate-1

                    -  Intermediate-2

                    -  High-risk score with transfusion dependence

               -  Chronic myelogenous leukemia meeting 1 of the following criteria:

                    -  In accelerated or blastic phase

                    -  Failed prior imatinib mesylate therapy

               -  Acute lymphoblastic leukemia meeting 1 of the following criteria:

                    -  In first CR with any of the following high-risk features:

                         -  Philadelphia chromosome present

                         -  Translocation t(4;11) present

                         -  WBC &gt; 30,000/mm³ (adult patients)

                         -  More than 4 weeks from initiation of treatment was required to achieve
                            CR (adult patients)

                         -  DNA index of near haploid (N=23 chromosomes) (pediatric patients)

                    -  In second or subsequent CR

                    -  Persistent disease as evidenced by 5-20% persistent blasts in bone marrow
                       after induction or salvage therapy

               -  Hodgkin's or non-Hodgkin's lymphoma meeting the following criteria:

                    -  Recurrent or refractory disease

                    -  Tumor ≤ 5 cm in diameter

               -  Myeloma or plasma cell neoplasm meeting 1 of the following staging criteria:

                    -  Stage III at presentation

                    -  Stage I-II at presentation

                         -  Not responding OR progressed after first-line therapy

               -  Chronic lymphocytic leukemia or Waldenstrom's macroglobulinemia with refractory
                  or progressive disease after first-line therapy

          -  No 5-6/6 HLA-matched related or 7-8/8 HLA-matched unrelated marrow or peripheral blood
             stem cell donor available

          -  No single 4-6/6 HLA-A, -B, or -DRB1-matched umbilical cord blood unit ≥ 3.5 x 10^7
             nucleated cells/kg available

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-2 OR Karnofsky or Lansky PS 70-100%

          -  Not pregnant

          -  Fertile patients must use effective contraception prior to and during study
             participation

          -  HIV negative

          -  Bilirubin &lt; 3.0 mg/dL

          -  AST and ALT ≤ 3 times upper limit of normal

          -  Creatinine &lt; 2.0 mg/dL OR creatinine clearance &gt; 50 mL/min

          -  Cardiac ejection fraction &gt; 50% by echocardiogram OR shortening fraction &gt; 27%

          -  No uncontrolled symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  FEV_1 &gt; 50% of normal

          -  Forced vital capacity &gt; 50% of normal

          -  DLCO normal

          -  Oxygen saturation &gt; 92% on room air (for patients &lt; 5 years of age)

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biological composition to busulfan and fludarabine phosphate

          -  No ongoing or active infection

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No other uncontrolled illness

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 4 weeks since prior and no concurrent surgery

          -  At least 4 weeks since prior and no other concurrent investigational or commercial
             agents or therapies for the malignancy, including chemotherapy, biologic therapy, or
             radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Voravit Ratanatharathorn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2007</study_first_submitted>
  <study_first_submitted_qc>January 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <last_update_submitted>February 26, 2016</last_update_submitted>
  <last_update_submitted_qc>February 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Voravit Ratanatharathorn</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute promyelocytic leukemia (M3)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>childhood acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>childhood acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <keyword>childhood acute myelomonocytic leukemia (M4)</keyword>
  <keyword>childhood acute monoblastic leukemia (M5a)</keyword>
  <keyword>childhood acute monocytic leukemia (M5b)</keyword>
  <keyword>childhood acute erythroleukemia (M6)</keyword>
  <keyword>childhood acute megakaryocytic leukemia (M7)</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>extramedullary plasmacytoma</keyword>
  <keyword>isolated plasmacytoma of bone</keyword>
  <keyword>monoclonal gammopathy of undetermined significance</keyword>
  <keyword>primary systemic amyloidosis</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>childhood acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>Burkitt lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>secondary myelofibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

